Single daily oral dose of gemfibrozil reduces postprandial hyperlipidemia in hyperlipidemic patients
- 作者：Descamps ; Olivier ; Hondekijn ; Jean-Claude ; Godrie ; Thierry ; Desager ; Jean-Pierre ; Heller ; Francis R.
- 关键词：gemfibrozil ; hyperlipidemia ; postprandial hyperlipidemia ; lipoprotein lipase ; hepatic lipase
- 刊名：Current Therapeutic Research
- 出版年：1998
- 期刊代码：75_0011393x
- 类别：med
- 出版时间：August, 1998
- 卷：59
- 期：8
- 页码：545-555
- 文件大小：742 K
摘要
This study analyzed the effects of a single daily oral dose (900 mg) of gemfibrozil on fasting and postprandial lipids in hyperlipidemic patients. In 13 patients with hypercholesterolemia or mixed hyperlipidemia, the intake of a single daily dose (900mg) of gemfibrozil for 3 weeks reduced the plasma concentration of total cholesterol (15 ± 7%), low-density lipoprotein cholesterol (9 ± 18%), and triglycerides (TGs) (39 ± 24%). During a vitamin A fat-loading test, TGs and retinyl palmitate (RP) responses were reduced significantly by gemfibrozil treatment, particularly in the chylomicron fraction. Plasma activity of hepatic lipase was increased significantly (9 ± 12%) by gemfibrozil treatment. The association between the apolipoprotein E phenotype and the postprandial changes in TGs and RP was not significant. As with high doses, a single 900-mg dose of gemfibrozil is capable of reducing postprandial hyperlipidemia. This effect involves both enhanced clearance of TGs of exogenous origin and reduced synthesis of TGs of hepatic origin. A unique property of gemfibrozil is its capacity, even in a single, 900-mg dose, to increase the activity of hepatic lipase